Cyclacel Pharmaceuticals, Inc. reported the updated mean survival data of its ongoing multi-center study on Sapacitabine conducted at the University of Texas MD Anderson Cancer Center. The company’s lead product candidate – sapacitabine –has been showing promising results in its phase 2 randomized trials. The mean survival rate in all 63 treated patients so far is 9 months, or 259 days.
http://bionews-tx.com/news/2013/05/01/cyclacel-reports-updated-phase-2-survival-data-of-sapacitabine-for-mds-conducted-at-md-anderson/
No comments:
Post a Comment